Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta shows late clinical disease relevance led by Angelman syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P28472. Start with Angelman syndrome, then reuse UniProt P28472 as the stable protein anchor across project notes and exports.
Start with Angelman syndrome, then reuse UniProt P28472 as the stable protein anchor across project notes and exports.
Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta shows late clinical disease relevance led by Angelman syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Angelman syndrome because it currently carries late clinical support. Linked drugs include GABOXADOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGamma-aminobutyric acid receptor subunit beta-3
Review this target as Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta, mapped to UniProt P28472. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit beta-3. Sequence length is 473 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta as ChEMBL target CHEMBL3430899, mapped to UniProt P28472. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta is the right protein anchor across sources, using UniProt P28472 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Angelman syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P28472 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gamma-aminobutyric acid receptor subunit beta-3 |
| UniProt Accession | P28472 |
| Component Type | Protein |
| Sequence Length | 473 aa |
Gamma-aminobutyric acid receptor subunit beta-3
Review this target as Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta, mapped to UniProt P28472. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit beta-3. Sequence length is 473 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta shows late clinical disease relevance led by Angelman syndrome. 3 more disease programs remain visible in the same review block.
Start review with Angelman syndrome because it currently carries late clinical support. Linked drugs include GABOXADOL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5612649 | 8.0 | EC50 | 10.0 | Preclinical |
| CHEMBL5613388 | 7.68 | EC50 | 21.0 | Preclinical |
| CHEMBL5612974 | 7.64 | EC50 | 23.0 | Preclinical |
| CHEMBL5612194 | 7.54 | EC50 | 29.0 | Preclinical |
| CHEMBL5613759 | 7.46 | EC50 | 35.0 | Preclinical |
| CHEMBL5613513 | 7.39 | EC50 | 41.0 | Preclinical |
| CHEMBL5613307 | 7.38 | EC50 | 42.0 | Preclinical |
| CHEMBL5612003 | 7.3 | EC50 | 50.0 | Preclinical |
| CHEMBL5612080 | 7.25 | EC50 | 56.0 | Preclinical |
| CHEMBL5614180 | 7.17 | EC50 | 68.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 3 | 41 | 6.8 |